

HATAY PHARMACEUTICAL JOINT STOCK COMPANY
REVIEWED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/6/2025



TABLE OF CONTENTS

CONTENTS	TRANG
BOARD OF MANAGEMENT'S REPORT	2 - 3
REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION	4
INTERIM CONSOLIDATED BALANCE SHEET	5 - 6
INTERIM CONSOLIDATED INCOME STATEMENT	7
INTERIM CONSOLIDATED CASH FLOW STATEMENT	8
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS	9 - 35

BOARD OF MANAGEMENT'S REPORT

We, members of Board of Management of Hatay Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") presents this Report together with the Company's reviewed Interim Consolidated Financial Statements for the period from 01/01/2025 to 30/6/2025.

The Board of Directors and the Board of Management

Members of the Board of Directors and the Board of Management who held the Company during the period from 01/01/2025 to 30/6/2025 and to the date of this report, are as follows:

The Board of Directors

Mr. Le Van Lo	Chairman
Mr. Le Anh Trung	Member
Ms. Le Viet Linh	Member
Mr. Le Xuan Thang	Member
Mr. Hoang Van Tue	Member
Mr. Hiroyasu Nishioska	Member
Mr. Keisuke Oshio	Member

The Board of Management

Mr. Le Xuan Thang	General Director –
Mr. Nguyen Ba Lai	Deputy General Director
Mr. Le Anh Trung	Deputy General Director
Ms. Le Viet Linh	Deputy General Director
Mr. Ngo Tuan Viet	Deputy General Director

Respective responsibilities of the Board of Management

Board of Management of the Company is responsible for preparing Interim Consolidated Financial Statements which give a true and fair view of the financial position, business operation results and cash flows of the Company in the period, in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations relating to the preparation and presentation of the Interim Consolidated Financial Statements. In the preparation of these Interim Consolidated Financial Statements, Board of Management is required to:

- Select suitable accounting policies and then consistently apply them;
- Make judgments and estimates that are reasonable and prudent;
- State whether appropriate accounting standards are respected or any application of material misstatements needs to be disclosed and justified in Interim Consolidated Financial Statements;
- Prepare the Interim Consolidated Financial Statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business; and
- Design and implement an effective internal control system for the purpose of properly preparing and presenting the Interim Consolidated Financial Statements so as to minimize risks and frauds.

BOARD OF MANAGEMENT'S REPORT

(continued)

Board of Management is responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the financial position of the Company and that the Interim Consolidated Financial Statements comply with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations relating to the preparation and presentation of the Interim Consolidated Financial Statements. Board of Management is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of frauds and other irregularities.

Board of Management confirms that the Company has complied with the above requirements in preparing these Interim Consolidated Financial Statements.

For and on behalf of the Board of Management,

HATAY PHARMACEUTICAL JOINT STOCK COMPANY



Le Xuan Thang
General Director

Hanoi, August 20, 2025

No. 208.01 -25/BC-TC/VAE

Hanoi, August 22, 2025

**REPORT ON REVIEW OF
INTERIM FINANCIAL INFORMATION**

**To: The Shareholders
Board of Directors and the Board of Management
Hatay Pharmaceutical Joint Stock Company**

We have reviewed the accompanying Interim Consolidated Financial Statements of Hatay Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company"), prepared on August 20, 2025, from page 05 to page 35, including: Interim Consolidated Balance Sheet as at 30/6/2025, Interim Consolidated Income Statement, Interim Consolidated Cash Flows Statement for the period then ended and Notes to the Interim Consolidated Financial Statements.

Board of Management's responsibility

Board of Management of the Company is responsible for the preparation and fair presentation of the Interim Consolidated Financial Statements of Company in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations relating to the preparation and presentation of the Interim Consolidated Financial Statements and for such internal control as Board of Management determines is necessary to enable the presentation of Interim Consolidated Financial Statements that are free from material misstatements whether due to fraud or error.

Auditors' responsibility

Our responsibility is to express a conclusion on these Interim Consolidated Financial Statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagement (VSRE) 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of Interim Consolidated Financial Statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Base on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Consolidated Financial Statements do not give a true and fair view, in all material respects, of the Interim Consolidated Financial position of the Company as at 30/6/2025, and of the interim consolidated results of its operations and its interim consolidated cash flows for the period then ended in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations related to the preparation and presentation of the Interim Consolidated Financial Statements.



Nguyen Thi Hong Van
Deputy General Director - Audit Director
Certificate of audit practice registration No. 0946-2023-034-1
For and on behalf of
VIETNAM AUDITING AND EVALUATION CO., LTD.

Form B01a - DN/HN

INTERIM CONSOLIDATED BALANCE SHEET

As at June 30, 2025

Unit: VND

ASSETS	Codes	Notes	30/6/2025	01/01/2025
A - CURRENT ASSETS	100		983,000,728,638	924,861,085,892
I. Cash and cash equivalents	110	V.01	157,117,080,604	90,269,672,873
1 Cash	111		77,117,080,604	70,269,672,873
2 Cash equivalents	112		80,000,000,000	20,000,000,000
II. Short-term financial investments	120		70,000,000,000	90,000,000,000
1 Held-to-maturity investments	123	V.02	70,000,000,000	90,000,000,000
III. Short-term receivables	130		200,021,406,672	192,360,480,643
1 Short-term trade receivables	131	V.03	123,031,080,019	127,407,266,728
2 Short-term advances to suppliers	132	V.04	71,930,682,320	59,380,091,165
3 Other short-term receivables	136	V.05	8,583,645,056	8,884,273,984
4 Provision for short-term doubtful debts	137	V.06	(3,524,000,723)	(3,311,151,234)
IV. Inventories	140	V.07	551,619,373,482	527,935,214,966
1 Inventories	141		553,580,423,233	529,896,264,717
2 Provision for devaluation of inventories	149		(1,961,049,751)	(1,961,049,751)
V. Other short-term assets	150		4,242,867,880	24,295,717,410
1 Value added tax deductibles	152		3,620,012,051	23,664,448,196
2 Taxes and other receivables from the State budget	154	V.15	622,855,829	631,269,214
B - NON-CURRENT ASSETS	200		1,020,481,990,939	1,001,444,167,114
I. Long-term receivables	210		-	-
II. Fixed assets	220		183,884,598,088	187,367,778,307
1 Tangible fixed assets	221	V.08	182,507,938,088	185,991,118,307
Cost	222		443,739,850,615	438,444,729,462
Accumulated depreciation	223		(261,231,912,527)	(252,453,611,155)
2 Intangible fixed assets	227	V.09	1,376,660,000	1,376,660,000
Cost	228		2,026,660,000	2,026,660,000
Accumulated amortization	229		(650,000,000)	(650,000,000)
III. Investment property	230		-	-
IV. Long-term assets in progress	240		812,699,877,711	790,109,801,102
1 Construction in progress	242	V.10	812,699,877,711	790,109,801,102
V. Long-term financial investments	250	V.02	19,525,815,642	19,335,631,790
1 Investment in joint-ventures, associates	252		19,525,815,642	19,335,631,790
2 Held-to-maturity investments	255		-	-
VI. Other long-term assets	260		4,371,699,498	4,630,955,915
1 Long-term prepayments expenses	261	V.11	4,371,699,498	4,630,955,915
TOTAL ASSETS (270=100+200)	270		2,003,482,719,577	1,926,305,253,006

(Notes from page 10 to page 35 are an integral part of these Interim consolidated Financial Statements)

Form B01a - DN/HN

INTERIM CONSOLIDATED BALANCE SHEET

As at June 30, 2025

(continued)

Unit: VND

RESOURCES	Codes	Notes	30/6/2025	01/01/2025
C - LIABILITIES	300		910,951,253,492	869,544,931,289
I. Current liabilities	310		809,194,798,020	767,752,475,817
1 Short - term trade payables	311	V.12	305,475,578,704	235,206,963,747
2 Short - term advances from customers	312	V.13	151,464,336,894	131,593,255,879
3 Taxes and amounts payable to the State budget	313	V.14	3,302,483,432	6,057,330,629
4 Payables to employees	314		14,800,889,567	15,735,720,457
5 Short-term accrued expenses	315	V.16	2,126,531,079	162,743,579
6 Short-term unearned revenue	318	V.17	1,497,365,896	909,298,387
7 Other current payables	319	V.18	809,239,523	608,008,522
8 Short-term loans and obligations under finance leases	320	V.15	325,692,156,052	373,273,974,867
9 Bonus and welfare funds	322		4,026,216,873	4,205,179,750
II. Long-term liabilities	330		101,756,455,472	101,792,455,472
1 Other long-term payables	337	V.18	4,843,500,000	4,879,500,000
2 Long-term loans and obligations under finance leases	338	V.15	96,912,955,472	96,912,955,472
D - EQUITY	400		1,092,531,466,085	1,056,760,321,717
I. Owner's equity	410	V.19	1,092,531,466,085	1,056,760,321,717
1 Owner's contributed capital	411		823,417,730,000	823,417,730,000
- Ordinary shares carrying voting rights	411a		823,417,730,000	823,417,730,000
2 Share premium	412		97,320,000,000	97,320,000,000
3 Other owners' equity	414		26,612,306,630	26,612,306,630
4 Treasury shares	415		(8,083,874,357)	(8,083,874,357)
5 Investment and development fund	418		10,749,248,213	10,749,248,213
6 Retained earnings	421		113,485,035,064	79,530,817,489
- Retained earnings accumulated to the prior period	421a		78,999,133,435	47,855,748,037
- Retained earnings of current period	421b		34,485,901,629	31,675,069,452
8 Non-controlling interest	429		29,031,020,535	27,214,093,742
II. Other resources and funds	430		-	-
TOTAL RESOURCES (440=300+400)	440		2,003,482,719,577	1,926,305,253,006

Hanoi, August 20, 2025

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by

Chief Accountant

Nguyen Thi Bich Ngoc

Hoang Van Tue



Le Xuan Thang

(Notes from page 10 to page 35 are an integral part of these Interim consolidated Financial Statements)

Form B02a- DN/HN

INTERIM CONSOLIDATED INCOME STATEMENT

For the period from 01/01/2025 to 30/6/2025

Unit: VND

ITEMS	Codes	Notes	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
1 Gross revenue from goods sold and services rendered	01	VI.1	1,070,569,562,879	999,692,287,014
2 Deductions	02	VI.2	209,869,070	243,758,050
3 Net revenue from goods sold and services rendered (10=01-02)	10	VI.3	1,070,359,693,809	999,448,528,964
4 Cost of sales	11	VI.4	963,034,045,601	898,553,441,477
5 Gross profit from goods sold and services rendered (20 =10-11)	20		107,325,648,208	100,895,087,487
6 Financial income	21	VI.5	16,272,793,859	9,171,050,471
7 Financial expenses	22	VI.6	13,245,813,064	11,717,873,151
In which: Interest expense	23		7,127,225,787	6,429,048,594
8 Profit or loss from associates, joint ventures	24		4,989,433,485	2,579,111,904
9 Selling expenses	25	VI.9	15,716,331,981	15,595,150,935
10 General and administration expenses	26	VI.9	60,775,790,178	49,428,512,010
11 Operating profit {30 = 20 + (21 - 22) + 24 - (25 + 26)}	30		38,849,940,329	35,903,713,766
12 Other income	31	VI.7	7,453,240,653	6,794,446,141
13 Other expenses	32	VI.8	630,379,075	8,576,831
14 Profit from other activities (40=31-32)	40		6,822,861,578	6,785,869,310
15 Accounting profit before tax (50=30+ 40)	50		45,672,801,907	42,689,583,076
16 Current CIT expense	51	VI.11	8,352,860,985	8,106,682,346
17 Deferred CIT expense	52		-	-
18 Net profit after corporate income tax (60=50-51-52)	60		37,319,940,922	34,582,900,730
19 The Parent company's net profit after tax	61		34,485,901,629	33,321,771,674
20 The non-controlling interests shareholders' net profit after tax	62		2,834,039,293	1,261,129,056
21 Basic earning per share	70	VI.12	418.82	404.68

Hanoi, August 20, 2025

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by

Chief Accountant

General Director

Nguyen Thi Bich Ngoc

Hoang Van Tue



Le Xuan Thang

(Notes from page 10 to page 35 are an integral part of these Interim consolidated Financial Statements)

INTERIM CONSOLIDATED CASH FLOWS STATEMENT

(Under indirect method)

For the period from 01/01/2025 to 30/6/2025

Unit: VND

ITEMS	Codes	Notes	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
I. Cash flow from operating activities				
1. Profit before tax	01		45,672,801,907	42,689,583,076
2. Adjustments for				
- Depreciation of fixed assets and investment properties	02		11,930,613,214	9,337,403,254
- Provisions	03		212,849,489	1,652,903,450
- Foreign exchange gain/loss arising from translating foreign currency items	04		5,299,727,203	1,192,027,911
- Gain, loss from investing activities	05		(12,925,105,580)	(4,446,506,218)
- Interest expense	06		7,127,225,787	6,429,048,594
3. Profit from operating activities before changes in working capital	08		57,318,112,020	56,854,460,067
- Increases, Decreases in receivables	09		8,970,502,024	52,609,391,572
- Increases, Decreases in inventories	10		(23,684,158,516)	(44,043,828,687)
- Increases, Decreases in payables (excluding interest payable, corporate income tax payable)	11		98,493,753,748	3,780,187,131
- Increases, Decreases in prepayment expense	12		259,256,417	358,495,842
- Interest expense paid	14		(7,173,238,312)	(6,495,284,521)
- Corporate income tax paid	15		(10,494,507,962)	(7,624,375,930)
- Other cash outflows	17		(178,962,877)	(199,700,000)
Net cash flow from operating activities	20		123,510,756,542	55,239,345,474
II. Cash flow from investing activities				
1. Acquisition and construction of fixed assets and other non-current assets	21		(40,457,863,446)	(68,812,137,228)
2. Proceeds from liquidation, disposal of fixed assets and other non-current assets	22		113,636,364	-
3. Cash outflows for lending, buying debt instruments of other entities	23		(70,000,000,000)	(140,000,000,000)
4. Cash recovered from lending, selling debt instruments of other entities	24		90,000,000,000	100,000,000,000
6. Cash recovered from capital investment of other entities	26		8,000,000,000	-
5. Interest earned, dividends and profits received	27		3,262,039,654	2,898,013,119
Net cash flow from investing activities	30		(9,082,187,428)	(105,914,124,109)
III. Cash flow from financial activities				
1. Proceeds from borrowing	33		381,263,054,367	324,607,532,614
2. Repayment of borrowing	34		(428,844,873,182)	(452,036,704,645)
3. Dividends and profit paid to owners	36		-	(41,170,130,000)
Net cash flow from financial activities	40		(47,581,818,815)	(168,599,302,031)
Net cash flow in the period (50 = 20+30+40)	50		66,846,750,299	(219,274,080,666)
Cash and cash equivalents at the beginning of the period	60		90,269,672,873	301,790,483,392
Effect of changes in foreign exchange rates	61		657,432	874,354
Cash and cash equivalents at the end of the period (50+60+61)	70	V.01	157,117,080,604	82,517,277,080

Prepared by

Nguyen Thi Bich Ngoc

Chief Accountant

Hoang Van Tue

HATAY PHARMACEUTICAL JOINT STOCK COMPANY



Le Xuan Thang

(Notes from page 10 to page 35 are an integral part of these Interim consolidated Financial Statements)

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)***I. General information****1. Structure of ownership**

Hatay Pharmaceutical Joint Stock Company (hereinafter referred to as “the Company”) is a joint stock company converted from a State-owned enterprise under Decision No. 1911 QD/UB dated December 21, 2000 of the People's Committee of Ha Tay province (now the People's Committee of Hanoi City). The Company was operated under the first Business Registration Certificate No. 030300015 dated January 10, 2001 issued by Hatay Authority for Planning and Investment (now Hanoi Authority for Planning and Investment). The Company has made 24 times of changes in its Business Registration Certificate.

Under the 24th amended Business Registration Certificate No. 0500391400 issued by Hanoi Authority for Planning and Investment dated January 15, 2024, the charter capital increase up to **VND 823,417,730,000** (*Eight hundred and twenty- three billion, four hundred and seventeen million, seven hundred and thirty thousand Vietnamese dong*)

Shares of the Company were listed on the Hanoi Stock Exchange under the securities code of DHT.

2. Operating industry

The company operates in the production and pharmaceutical business and services./.

3. Principal activities

- Production of medicines, pharmaceutical chemicals, and medicinal materials. Details: Manufacturing of medicines, pharmaceuticals, medicinal materials, cosmetics, medicinal foods, and medical equipment;
- Distribution of medicines, medical equipment, cosmetics, and hygiene products in specialized stores. Details: The right to distribute medicine and medicinal materials produced by the facility itself in Vietnam.
- Wholesale of other Household Goods. Details: The right to distribute and wholesale goods by legal provisions (excludes the following items: national reserve goods, rice, cane sugar, beet sugar, cigarettes, cigars, crude oil and processed oil, explosives, books, newspapers and magazines, precious metals, precious stones, and any recorded items made of all materials);
- The right to wholesale medicines and medicinal materials produced by the facility itself in Vietnam; Selling medicines and medicinal materials to pharmacies and medicinal materials according to Clause 10, Article 91 of Decree No. 54/2017/ND-CP;
- Real estate business, land use rights owned, used, or leased business. Details: Real estate business (excluding investments in building infrastructure for cemeteries and graveyards to transfer land use rights attached to that infrastructure);
- Other business support services are not classified elsewhere. Details: Medicines storage service; The right to import and export goods according to the law (excluding goods on the national reserve list and goods in Appendix No. 01 and Appendix No. 02 of Circular 34/2013/TT-BCT); The right to import and export medicines and medicinal materials.
- Production of other foods is not classified elsewhere. Details: Production of functional foods; Wholesale of foods. Details: The right to distribute and wholesale goods according to the law (excluding goods on the national reserve list and rice, cane sugar, beet sugar)/.

The Company's Head Office: No.10A Quang Trung, Ha Dong Ward, Hanoi City, Vietnam.

4. Normal production and business cycle

The normal operating cycle of the Company will last no more than 12 months.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS *(continued)**(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)***5. The Company's structure*****a/ Information about the Company's dependent accounting units:***

- | | |
|---|---|
| 1. Pharmaceutical Branch No. 01 | - Address: 4th floor, 10A Quang Trung, Ha Dong Ward, Hanoi City, Vietnam |
| 2. Branch of Ha Tay Pharmaceutical Joint Stock Company in Nghe An | - Address: No.80 Nguyen Trai, Vinh Phu Ward, Nghe An Province, Vietnam |
| 3. Ba Vi Pharmaceutical Branch | - Address: Van Trai Village, Hanoi City, Vietnam |
| 4. Thuong Tin Pharmaceutical Branch | - Address: No. 251 Pho Ga, Thuong Tin Commune, Vietnam |
| 5. My Duc Pharmaceutical Branch | - Address: Te Tieu Village, My Duc Commune, Hanoi City, Vietnam |
| 6. Oriental Medicine and Medical Supplies Branch | - Address: 78 Quang Trung, Ha Dong Ward, Hanoi City, Vietnam |
| 7. Branch of Ha Tay Pharmaceutical Joint Stock Company in Thai Binh | - Address: Lot 13, Group 22, Doc Den Street Tran Lam Ward resettlement area, Hung Yen Province, Vietnam |
| 8. Phu Xuyen Pharmaceutical Branch | - Address: My Lam Sub-area, Phu Xuyen Commune, Hanoi City, Vietnam |
| 9. Son Tay Pharmaceutical Branch | - Address: No. 122 Le Loi, Le Loi Ward, Hanoi City, Vietnam |
| 10. Quoc Oai Pharmaceutical Branch | - Address: Quoc Oai Town, Quoc Oai Commune, Hanoi City, Vietnam |
| 11. Ung Hoa Pharmaceutical Branch | - Address: Hoang Xa Village, Van Dinh Commune, Hanoi City, Vietnam |
| 12. Thanh Oai Pharmaceutical Branch | - Address: Kim Bai Town, Thanh Oai Commune, Ha Noi City, Vietnam |
| 13. Thach That Pharmaceutical Branch | - Address: Road No.84, Thach That Commune, Hanoi City, Vietnam |
| 14. Branch of Ha Tay Pharmaceutical Joint Stock Company | - Address: 4th Floor, No. 10A Quang Trung, Ha Dong Ward, Hanoi City, Vietnam |

b) Details of Subsidiaries which are consolidated into these Interim Consolidated Financial Statements for the period from 01/01/2025 to 30/6/2025 as follows:

- | | |
|--|--|
| 1. Ha Tay Pharmaceutical and Medical Equipment JSC | Address: No. 10, Alley 4, Xom street, Phu Luong Ward, Hanoi City, Vietnam |
| | Principal activities: Manufacturing Functional Foods and trading Medical Equipment |
| | Proportion of ownership interest: 50.63% |
| | Proportion of voting right: 50.63% |

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

c) Details of Associates which are reflected in the Interim Consolidated Financial Statements using the equity method for the period from 01/01/2025 to 30/6/2025 as follows:

- | | | |
|----|--|--|
| 1. | Southern Hataphar Company Limited | Address: No. 62 Tran Van Giap, Phu Thanh Ward, Ho Chi Minh City, Vietnam
Principal activities: Trading in medicines, functional foods, cosmetics, medical equipment and instruments
Proportion of ownership interest: 48.28%
Proportion of voting right: 48.28% |
| 2. | Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC | Address: No. 80 Quang Trung, Ha Dong Ward, Hanoi City, Vietnam
Principal activities: Trading and distribution of pharmaceutical products
Proportion of ownership interest: 49.00%
Proportion of voting right: 49.00% |

6. Disclosure of information comparability in the Interim Consolidated Financial Statements

The respective information and figures presented in the Interim Consolidated Financial Statements of the Company for the period from 01/01/2025 to 30/6/2025 are comparative.

7. Number of employees

The number of employees of the Company as at 30/6/2025 is 585 (As at 31/12/2024 is 780).

II. Accounting period, accounting currency

1. Accounting period

The Company's accounting period begins on 01/01 and ends on 31/12 every year.

These Interim Consolidated Financial Statements are prepared for the period from 01/01/2025 to 30/6/2025.

2. Accounting currency

The currency used in accounting is Vietnam dong ("VND") accounted under the principle of historical cost, in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and the legal regulations related to the preparation and presentation of Interim Consolidated Financial Statements.

III. Applied accounting regime and standards

1. Applied accounting regime and standards

The Company applies Vietnamese Accounting regime and Vietnamese Accounting Standards for enterprises promulgated under the Circular No. 200/2014/TT-BTC dated 22/12/2014 by Ministry of Finance guiding the Accounting Regime for Enterprises and Circular No. 53/2016/TT-BTC dated 21/03/2016 by Ministry of Finance regarding amendment to some articles of Circular No. 200/2014/TT-BTC; prepares and presents the Interim Consolidated Financial Statements in accordance with Circular No. 202/2014/TT-BTC dated 22/12/2014 by Ministry of Finance.

2. Statement on the compliance to Accounting Standards and Accounting regime

The Company's Interim Consolidated Financial Statements are prepared and presented in accordance with Vietnamese Accounting Standards and current Vietnamese Accounting regime for enterprises and

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

the laws and regulations in relation to the preparation and presentation of Interim Consolidated Financial Statements.

IV. Significant accounting policies**1. Basis for the Consolidation of Interim Consolidated Financial Statements**

The Interim Consolidated Financial Statements include Interim Separate Financial Statements of the Company and Interim Financial Statements of companies under the control of the Company (subsidiaries) prepared as at 30/6/2025. The control means the Company is able to control financial policies and operations of investee companies in order to get economic benefits from these companies.

All transactions and balances between companies in the same Group are canceled out upon consolidating the Interim Financial Statements.

Non-controlling interest

Non-controlling interest in net assets of subsidiaries are determined as a separate item from the part of owner's equity of shareholders of the parent company. Non-controlling interest (NCI) consists of the value of non-controlling interest as at the initial consolidated date and changes in NCI in the total equity changes from the consolidated date. Loss amounts incurred at subsidiaries must be allocated corresponding to the ownership of non-controlling, in case of those loss amounts are greater than the ownership of non-controlling in net assets of subsidiaries.

Investment in associates

An associate is an entity over which the Company has significant influence and that is neither a subsidiary nor an interest in the joint venture. Significant influence is the power to participate in the investee's financial and operating policy decisions but not control or joint control over those policies. Normally, the Company is considered a significant influence when the capital owners have more than 20% of the vote right at the entity receiving the investment. The investment in associates is recorded as an equity method.

According to the equity method, the investment is initially recorded on the consolidated balance sheet at cost, then it is adjusted by post-acquisition changes in the Company's share of the net assets of the associate. Goodwill arising from the investment in the associates is reflected in the residual value of the investment. The Company does not allocate this goodwill but conducts an annual assessment to determine whether it is impaired. The consolidated income statement reflects the Company's share of the associates' results of operations after acquisition.

When the Company's share of the associates's losses, which the Company must share, exceeds the Company's interest in the associates accounted for using the equity method, the carrying value of the investment will be reduced to zero, and future losses will no longer be recognized, except for losses within the scope where the Company is obligated to pay or has paid on behalf of the associates.

2. Foreign exchange rates applied in accounting

Exchange rates for transactions denominated in foreign currencies are transaction exchange rates of Commercial Bank on the transaction date.

Exchange rates for re-translation of monetary items in foreign currencies at the reporting date are the rates stated by the Commercial Bank of Branch on the reporting date.

Thereby:

- Exchange rates for re-translation of items in foreign currencies and classified as assets are the buying rates stated by the Commercial Bank on the reporting date.
- Exchange rates for re-translation of items in foreign currencies and classified as liabilities are the selling rates stated by the Commercial Bank on the reporting date.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

3. Estimates

The preparation of Interim Consolidated Financial Statements in conformity with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to the preparation and presentation of Interim Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the Interim Consolidated Financial Statements and the reported amounts of revenues and expenses during the period. Although these accounting estimates are based on the management's best knowledge, actual results may differ from those estimates.

4. Principle of recognizing cash and cash equivalents

Cash and cash equivalents comprise cash in hand, demand deposits and other short-term of less than 3 months, liquid investments that are readily convertible to a known amount of cash and which are subject to an insignificant risk of changes in value.

5. Accounting principle for financial investments***Held-to-maturity investments***

Held-to maturity investments comprise investment including that the Company has positive intent and or ability to hold to the maturity. Held-to-maturity investments including: term deposits in banks.

Held-to-maturity investments are recognized on a trade date basis and are initially measured at acquisition price plus directly attributable transaction costs. Post-acquisition interest income from held-to-maturity investments is recognized in the income statement on accrual basis. Pre-acquisition interest is deducted from the cost of such investments at the acquisition date.

Held-to-maturity investments are measured at cost less provision for doubtful debts.

Current accounting regulations make provision for doubtful debts of investments held to maturity.

6. Accounting principle for receivables

Receivables are presented as net book value less allowance for doubtful and bad debts. Classification of receivables is made on the following principle:

- Trade accounts receivable consist of receivables with their commercial nature arising from transactions with their purchasing-selling nature between the Company and buyers who are independent entities from the Company.
- Other receivables consist of receivables with their non-commercial nature, not related to transactions with their purchasing-selling nature.

Allowance for doubtful and bad debts is made for each doubtful or bad debt based on age of each debt amount or estimated loss that may incur because debtors are insolvent under liquidation, bankruptcy or similar hardship.

Increase, decrease in provision for bad and doubtful debts to be made at the cut-off date for Interim Consolidated Financial Statements shall be recognized into general administration expenses.

7. Principle for recognizing inventories

Inventories are recognized at the lower price between historical cost and net realizable value. Historical cost of inventories consists of expenses of acquisition, processing and other directly related expenses (if any) incurred to bring inventories to their present location and condition.

Net realizable value is determined as the estimated selling price of inventories during the normal business period minus the estimated costs to complete and necessary estimated costs to sell.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

The value of inventories is determined by the Weighted Average Method and accounted for by the perpetual method.

Provision for devaluation in inventories: Provision for devaluation in inventories is made for the respective category of inventories with its cost being higher than the net realizable value. An increase or decrease in the provision for devaluation in inventories to be made at the cut-off date shall be recognized in the cost of sales.

8. Principle for tangible fixed asset recognition and depreciation

Tangible fixed assets are recognized at their historical cost, presented in the Interim Consolidated Balance Sheet under the items of historical cost, accumulated depreciation and carrying amount.

The historical cost of procured tangible fixed assets includes their purchase price (excluding trade discount or other discount), taxes and directly related costs to bring such assets into the ready-for-use state.

Historical cost of fixed assets which are constructed by contractors includes value of completed and handover works, directly-related costs and stamp duty.

The expenses incurred after the initial recognition of tangible fixed assets are recorded as the increases of historical cost of assets when these expenses are sure to increase economic benefits in the future. The incurred expenses which do not satisfy the above conditions are recognized into production and business operation expenses in the year.

The Company applied straight-line depreciation method to tangible fixed assets. Tangible fixed assets are accounted and classified into groups by their nature and purpose of utilization in the Company's production and business operation, including:

<i>Type of fixed assets</i>	<i>Depreciation duration <years></i>
- Building and structures	06 - 25
- Machinery, equipment	06 - 10
- Means of transportation	03 - 10
- Management equipment, tools	03 - 10
- Other tangible fixed assets	04

Gains and losses arising from asset liquidation are the difference between the liquidation proceeds and the carrying amount of the assets and are recorded in the income statement.

9. Principle for intangible fixed asset recognition and amortization

Intangible fixed assets are recognized at their historical cost, presented in the Interim Consolidated Balance Sheet under the items of historical cost, accumulated amortization and carrying amount.

Historical cost of acquired intangible fixed assets consists of their total purchase price to bring the assets to their state of ready-to-use. The costs arising after initial recognition of intangible fixed assets are recorded as production costs in the period excluding specific costs of a specific intangible asset, enabling an increase in future economic benefits.

When an intangible fixed asset is sold or disposed, historical cost and accumulated depreciation are written off and gain or loss from disposal is recognized into income or expense in the period.

Intangible fixed assets of the Company include: Land use right and computer software.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

Land use right

Land use rights encompass all costs incurred by the Company that are directly related to the long-term land use rights at 62 Tran Van Giap, Phu Thanh Ward, Ho Chi Minh City, Viet Nam.

Computer software

Costs in relation to translation computer software are not an integral part of the relevant capitalized hardware. Historical costs of computer software is the whole expenditure paid by the Company until the software are put into use. Computer software are amortized on straight-line basis in 03 years.

10. Principle for recognizing construction in progress

Construction in progress for production, rental, administrative purposes or for other purposes are recognized at their historical cost. This cost includes all expenses necessary to prepare the asset for its intended use in accordance with the Company's accounting policy. Depreciation on these assets starts, as it does with other assets, once they are ready for their intended use.

11. Principle for recognition and allocation of prepayment expenses

Prepayment expenses consist of actual expenses incurred but related to the business performance of many accounting periods. Prepayment expenses include: factory repair costs, tools, instruments issued for use awaiting for allocation and other expenses awaiting for allocation.

Factory repair costs are one-time costs with large value which were exported for use and allocated into expenses on straight-line basis no more than 03 years.

Tools, instruments are one-time costs with large value which were exported for use and allocated into expenses on straight-line basis no more than 03 years.

12. Accounting principle for liabilities

Liabilities are amounts payable to suppliers and other subjects. Liabilities comprise trade accounts payable and other payables. Liabilities are not recorded at lower amounts than payment obligations.

Classification of liabilities is made on the following principle:

- Trade accounts payable comprises liabilities with their commercial nature arising from purchasing goods, services, assets and the suppliers are independent from buyers.
- Other amounts payable comprise amounts payable with their non-commercial nature, not related to transactions of purchasing, selling and supplying goods, services.

Liabilities are monitored by details of each item and due date. Liabilities denominated in foreign currencies are revalued at the selling rates stated by Vietnam Joint Stock Commercial Bank for Industry and Trade.

13. Principle for recognizing loans

Loans are recognized on the basis of receipts, bank vouchers, loan agreements.

Loans are monitored by details of each item and due date.

14. Principle for recognition and capitalization of borrowing costs

Borrowing costs consist of loan interest and other costs that are incurred in direct connection with the borrowings.

Borrowing costs are recognized into operation and production costs in the period if arising, unless they are capitalized in accordance with Accounting Standard "Borrowing Costs". As a result, borrowing costs which directly relate to procurement, construction investment or production of properties that need a quite long period to be completed for putting into operation or business shall be plus in historical cost of

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

property until such property would be put into use or business. The incomes arising from the temporary investment of loans are deducted from the historical cost of related assets. For a separate loan for the construction of fixed assets and investment property, borrowing cost is capitalized even if the construction period is less than 12 months.

15. Principle for recognizing accrued expense

Accrued expenses consist of borrowing cost payable, 60th Anniversary Company expenses, including actual expenses incurred in the reporting period but unpaid because no invoice was available or accounting documents are missing, being recognized in operating expenses of the reporting period.

Accrued expenses on production and business expenses in the period are calculated strictly with reasonable and reliable evidence on the expenses to be accrued in the period to ensure the accounting expenses payable to be accounted will match the actual costs incurred.

16. Principle for recognizing unearned revenue

Unearned revenue is the amount received in advance from customers for one or more accounting periods for office rental.

17. Principle for recognizing owner's equity

Capital investment of the Company's owners is recognized by shareholders' actual capital contribution.

Share premium is recognized as the difference between the issuance price and the par value of the shares during the initial issuance, additional issuance, the difference between the re-issuance price and the book value of treasury shares, and the equity component of convertible bonds upon maturity. Direct costs related to additional share issuance and the re-issuance of treasury shares are deducted from the Share premium.

Other owners' equity is formed by additions from business performance, asset revaluation, and the remaining value between the fair value of donated, gifted, or sponsored assets after deducting any payable taxes (if any) related to these assets.

Treasury shares are shares repurchased by the Company that were originally issued by the Company itself. The payment, including related transaction costs, is recognized as treasury shares and is reflected as a deduction in equity. Upon re-issuance, the difference between the re-issuance price and the book value of the treasury shares is recorded under the item "Share premium".

Retained earnings are the profit amounts from the enterprise's business operation after deducting CIT expenses this period.

Profit after corporate income tax is allocated to shareholders right after funds are made for under the Corporation Article of the Company as well as legal regulations and upon approval of the Annual General Meeting.

Dividend is recognized as a payable upon approval by the Annual General Meeting of shareholders.

18. Principle and method of recognizing revenue, other income

Revenue of the Company includes revenue from selling pharmaceutical products and revenue from interest on deposits.

Revenue from selling goods is recognized upon simultaneously meeting the following conditions as follows:

- The Company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer;

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

- The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;
- Turnover is determined with relative certainty. In case the contract specifies that buyers have the right to return goods or products that were bought under specific terms, the revenue is only recognized when these specific terms no longer exist and the buyers have no right to return goods or products (except for the case that customers can return goods as exchange to other goods or services);
- The Company gained or will gain economic benefits from the sale transaction; and
- It is possible to determine the costs related to the goods sale transaction.

Interest income

Interest amounts are recognized on accrual basis, being determined on balances of deposits and actual interest rates in the period.

The company's other income including revenue from house rentals, fixed asset liquidations, labor rentals, and other incomes, is recorded based on house rental contracts, fixed asset liquidation contracts, financial invoices, receipts, bank documents, and other related accounting documents.

19. Tax liabilities***Value added tax (VAT)***

The Company declares and calculates VAT under the guidelines of current Taxation Law.

Corporate income tax

Corporate income tax presents the total amount of current tax payable.

Current tax payable is calculated on the taxable profit in the period. Taxable income differs from net profit presented in the Interim Consolidated Income Statement because taxable income does not include assessable incomes or expenses or deductible ones in other years (including losses carried forward, if any) and it further excludes items that are non-taxable or non-deductible.

The Company applies the corporate income tax rate of 20% on taxable profits.

The corporate income tax of the Company is determined in conformity with current tax regulations. However, these regulations may change from time to time, and the final determination of corporate income tax will depend on the tax check results provided by the competent tax authorities.

Other taxes

Other taxes and fees are declared and paid to the local tax authorities in compliance with the current regulations of the State.

20. Segment reporting

A segment is a distinguishable component of the Company that is engaged either in providing related products or services (business segment) or in providing products or services within a particular economic environment (geographical segment) that is subject to risks and returns that are different from those of other business segments. The Board of Management believes that the Company's principal activities are the production and sale of pharmaceutical products and are mainly distributed in the territory of Vietnam. Therefore, the Company does not present segment reports by business segment and by geographical area in accordance with Vietnamese Accounting Standard No. 28 - Segment reporting.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

V. Additional information of items presented in the Interim Consolidated Balance Sheet

1. Cash and cash equivalents

	30/6/2025	01/01/2025
	VND	VND
Cash	77,117,080,604	70,269,672,873
Cash on hand	7,518,894,656	13,278,124,220
Cash in bank	69,598,185,948	56,991,548,653
VND	69,480,961,878	56,759,111,855
USD	106,249,299	224,301,351
EUR	10,974,771	8,135,447
Cash equivalents (*)	80,000,000,000	20,000,000,000
Bank deposits with terms of less than 3 months (*)	80,000,000,000	20,000,000,000
Total	157,117,080,604	90,269,672,873

(*) Bank deposits at Vietnam Joint Stock Commercial Bank with a term of 03 months.

2. Financial investments

a) Held-to-maturity investments

	30/6/2025		01/01/2025	
	VND		VND	
	Cost	Carrying amount	Cost	Carrying amount
Short-term	70,000,000,000	70,000,000,000	90,000,000,000	90,000,000,000
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch (1)	40,000,000,000	40,000,000,000	90,000,000,000	90,000,000,000
Viet A Commercial Joint Stock Bank - Ha Dong Branch (2)	30,000,000,000	30,000,000,000	-	-
Total	70,000,000,000	70,000,000,000	90,000,000,000	90,000,000,000

(1) Deposit contract No. 320/2025/9160 dated March 31, 2025, amount of VND 40 billion with 06 months term, interest rate of 4.8%/year, interest paid at term end.

(2) Term deposits at Viet A Commercial Joint Stock Bank - Ha Dong Branch, including:

+ Deposit contracts No. 75/HDTG/VAB-DHT dated March 27, 2025, amount of VND 20 billion with 6 months term, interest rates from 6.0%/year, interest paid at term end; and

+ Deposit contracts No. 82 dated April 01, 2025, amount of VND 10 billion with 6 months term, interest rates from 6.0%/year, interest paid at term end.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)***b) Investment in other entities**

	30/6/2025		01/01/2025	
	VND		VND	
	Cost	Adjustment in the period	Cost	Adjustment in the period
		Book value		Book value
<i>Investment in associates</i>				
Southern Hataphar Company Limited (i)	700,000,000	267,262,230	700,000,000	124,811,232
Hanoi Technical College of Medicine Pharmacy (ii)	-	-	3,287,565,579	-
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC (iii)	2,450,000,000	16,108,553,412	2,450,000,000	12,773,254,979
Total	3,150,000,000	16,375,815,642	6,437,565,579	12,898,066,211
		19,525,815,642		19,335,631,790

- Summary of the operations of the associated companies during the period:

(i) Under the 7th amended Business Registration Certificate dated June 15, 2017, the Company invested VND 700,000,000 in Southern Hataphar Company Limited, equivalent to 48.28% of the charter capital. At the end of the year, the Company invested VND 700,000,000, equivalent to 48.28% of the charter capital.

(ii) According to the Resolution from extraordinary general meeting of shareholders of Ha Tay Pharmaceutical Joint Stock Company No. 875/NQ-DHT dated August 22, 2023, the Board of Shareholders approved the transfer of the capital contribution of Ha Tay Pharmaceutical and Medical Equipment JSC at Hanoi College of Medical Technology and Pharmacy. As at January 24, 2025, the transfer of the above capital contribution has been completed. Accordingly, from January 24, 2025, Hanoi College of Medical Technology and Pharmacy is no longer an Associate of the Company.

(iii) Under the 2nd amended Business Registration Certificate dated June 20, 2023, the Company invested VND 4,900,000,000 in Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC, equivalent to 49% of the charter capital. During the period, the Company received stock dividends in the amount of 490,000 shares. At the end of the accounting period, the Company held 49% of the charter capital, equivalent to 980,000 shares of Hataphar Healthcare Vietnam High-Tech Pharmaceutical Joint Stock Company (the beginning of the year balance was 490,000 shares, equivalent to 49% of the charter capital). According to the 3rd amended Business Registration Certificate dated June 11, 2025, the Company invested in Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company with a value of VND 9,800,000,000, equivalent to 49% of the charter capital.

The associated companies are functioning normally, with no significant changes compared to the previous year.

The significant transactions between the Company and the associated companies are detailed in note VIII.2

As at June 30, 2025, it has not been possible to determine the fair value of the investments mentioned above due to a lack of market prices or insufficient information needed for assessment. The fair value of these investments may differ from their book value.

Form B 09a - DN/HN

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

3. Trade receivable

	30/6/2025		01/01/2025	
	VND		VND	
	Amount	Provision	Amount	Provision
a) Short-term	123,031,080,019	(3,524,000,723)	127,407,266,728	(3,311,151,234)
- Some large balances in trade receivables:				
Thanh Vinh Pharmaceutical and Medical Materials JSC	2,440,807,940	-	1,309,526,370	-
Thuan Anh Pharmaceutical Company Limited	6,368,579,175	-	9,454,374,467	-
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	25,102,003,395	-	63,375,349,280	-
EU Pharmaceutical JSC	867,883,084	-	1,450,206,484	-
Duc Tam Company Limited	1,235,312,186	-	868,896,298	-
Vinh Gia Pharmaceutical JSC	2,830,381,947	-	2,869,454,757	-
Truong Huy Company Limited	2,984,786,591	-	4,119,196,070	-
Hanh Ha Pharmaceutical JSC	2,449,720,007	-	4,821,708,418	-
Vinaplant Pharmaceutical JSC	6,927,272,979	-	5,131,474,842	-
Stabled Pharmaceutical Company Limited	2,533,617,628	-	4,380,639,034	-
Kim Long Investment JSC	1,565,371,425	-	2,879,529,852	-
T&T Equipment JSC	8,741,969,164	-	837,406,953	-
Life Pharmaceutical and Medical Equipment JSC	12,587,911,990	-	-	-
California USA Pharmaceutical Co., Ltd	11,128,023,588	-	-	-
Thu Duc City Hospital	1,901,125,000	(1,798,460,000)	1,992,665,000	(1,722,334,000)

b) Trade receivables from related parties: Details are presented in Note VIII.2

4. Advances to suppliers

	30/6/2025	01/01/2025
	VND	VND
a) Short-term	71,930,682,320	59,380,091,165
- Some large balances in Advances to suppliers:		
SDC Design and Construction JSC	4,547,744,699	-
Panpharma GMBH	-	13,154,807,906
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	3,136,254,281	1,709,103,940
XL Laboratories PVT.,LTD	2,900,559,780	18,931,343,957
Bliss Pharma distribution and consul Tancy corp	18,544,678,160	2,364,270,000
Pharmametics products a division of max Biocare Pty Ltd	518,960,000	3,043,217,797
Delta Pharma Ltd	32,298,302,671	5,145,850,347
Thang Long Elevator Equipment Group Co., Ltd.	-	824,800,000

b) Advances to suppliers from related parties: Details are presented in Note VIII.2

Form B 09a - DN/HN

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

5. Other receivables	30/6/2025		01/01/2025	
	VND		VND	
	Amount	Provision	Amount	Provision
Short - term				
<i>Other receivables</i>	<i>1,871,616,145</i>	-	<i>2,059,376,373</i>	-
Estimated interest receivable	1,826,958,916	-	1,979,397,260	-
<i>Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch</i>	<i>1,361,753,425</i>	-	<i>1,979,397,260</i>	-
<i>Viet A Commercial Joint Stock Bank - Ha Dong Branch</i>	<i>465,205,491</i>	-	-	-
Others	44,657,229	-	79,979,113	-
<i>Advances</i>	<i>304,986,411</i>	-	<i>417,855,111</i>	-
Hoang Thi Minh Nguyet	-	-	300,000,000	-
Nguyen Van Phuc	100,000,000	-	-	-
Others	204,986,411	-	117,855,111	-
<i>Mortgages, deposits</i>	<i>6,407,042,500</i>	-	<i>6,407,042,500</i>	-
Management Board of Hoa Lac High-Tech Park (*)	6,407,042,500	-	6,407,042,500	-
Total	8,583,645,056	-	8,884,273,984	-

(*) The deposit for the Management Board of Hoa Lac High-Tech Park to ensure the implementation of the "Hataphar High-Tech Pharmaceutical Factory" is outlined in the Investment Project Implementation Guarantee Deposit Agreement No. 06/TTKQ dated November 27, 2020.

6. Bad debts	30/6/2025		01/01/2025	
	VND		VND	
	Cost	Recoverable amount	Cost	Recoverable amount
Total value of receivables, that are overdue and difficult to recover				
Thu Duc City Hospital	1,901,125,000	102,665,000	1,866,065,000	143,731,000
Others	2,257,310,216	531,769,493	1,678,633,431	89,816,197
Total	4,158,435,216	634,434,493	3,544,698,431	233,547,197

7. Inventories	30/6/2025		01/01/2025	
	VND		VND	
	Cost	Provision	Cost	Provision
Purchased goods in transit	25,375,807,991	-	65,940,100,079	-
Raw materials	104,301,670,186	-	107,094,027,941	-
Tools and supplies	331,408,119	-	543,682,370	-
Work in progress	-	-	1,838,766,875	-
Finished goods	37,015,908,417	(1,961,049,751)	43,390,614,449	(1,961,049,751)
Goods	386,555,628,520	-	311,089,073,003	-
Total	553,580,423,233	(1,961,049,751)	529,896,264,717	(1,961,049,751)

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Address: No.10A Quang Trung, Ha Dong Ward, Hanoi City, Vietnam

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/6/2025

Form B 09a - DN/HN

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

8. Increases, decreases in tangible fixed assets

Unit: VND

Items	Building and structures	Machinery, equipment	Means of transportation, transmission equipment	Office equipment and tools	Other fixed assets	Total
<i>Cost</i>						
Balance as at 01/01/2025	165,433,649,181	254,464,404,513	12,984,271,801	5,123,121,467	439,282,500	438,444,729,462
Purchase in the period	-	4,329,456,102	1,071,875,548	-	-	5,401,331,650
Construction completed	3,046,101,345	-	-	-	-	3,046,101,345
Liquidation of fixed assets	-	(671,688,703)	(1,600,188,615)	(880,434,524)	-	(3,152,311,842)
Balance as at 30/6/2025	168,479,750,526	258,122,171,912	12,455,958,734	4,242,686,943	439,282,500	443,739,850,615
<i>Accumulated depreciation</i>						
Balance as at 01/01/2025	94,621,095,499	144,365,098,744	8,258,164,805	4,769,969,606	439,282,500	252,453,611,155
Depreciation in the period	3,589,496,520	7,933,990,024	367,250,883	39,875,787	-	11,930,613,214
Liquidation of fixed assets	-	(671,688,703)	(1,600,188,615)	(880,434,524)	-	(3,152,311,842)
Balance as at 30/6/2025	98,210,592,019	151,627,400,065	7,025,227,073	3,929,410,869	439,282,500	261,231,912,527
<i>Net book value</i>						
As at 01/01/2025	70,812,553,682	110,099,305,769	4,726,106,996	353,151,861	-	185,991,118,307
As at 30/6/2025	70,269,158,507	106,494,771,847	5,430,731,661	313,276,074	-	182,507,938,088

- Historical cost of fixed assets which have been fully depreciated but still in use: VND 164,003,175,713. (As at 31/12/2024: VND 167,628,149,698)

Form B 09a - DN/HN

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

9. Increases, decreases in intangible fixed assets

Unit: VND

Items	Accounting software	Land use rights	Total
<i>Cost</i>			
Balance as at 01/01/2025	650,000,000	1,376,660,000	2,026,660,000
Balance as at 30/6/2025	650,000,000	1,376,660,000	2,026,660,000
<i>Accumulated amortization</i>			
Balance as at 01/01/2025	650,000,000	-	650,000,000
Balance as at 30/6/2025	650,000,000	-	650,000,000
<i>Net book value</i>			
As at 01/01/2025	-	1,376,660,000	1,376,660,000
As at 30/6/2025	-	1,376,660,000	1,376,660,000

- Historical cost of intangible fixed assets which have been fully depreciated but still in use: VND 650,000,000. (As at 31/12/2024: VND 650,000,000)

10. Construction in progress

	30/6/2025 VND	01/01/2025 VND
Hataphar High-Tech Pharmaceutical Factory (*)	800,058,857,577	783,197,217,350
Glass bottle washing and sterilization equipment	925,925,926	-
Cost of research and development of pharmaceutical products	11,715,094,208	6,912,583,752
Total	812,699,877,711	790,109,801,102

The investment project is progressing according to the Minutes of the Extraordinary Shareholders' Meeting No. 855/BB-DHT and Resolution No. 856/NQ-DHT, both dated August 26, 2020, which approved the "Hataphar High-Tech Pharmaceutical Factory." In which, the interest and borrowing guarantee fee capitalized into the Project accumulated to June 30, 2025 is VND 24,494,318,831 (As of January 01, 2025 is VND 19,780,939,500).

11. Prepayments

	30/6/2025 VND	01/01/2025 VND
<i>Long-term</i>		
Issued tools and instruments awaiting for allocation	1,632,980,550	1,378,549,737
Repair and renovation costs	2,721,010,617	3,228,447,845
Other Prepayments	17,708,331	23,958,333
Total	4,371,699,498	4,630,955,915

12. Trade payables

	30/6/2025 VND		01/01/2025 VND	
	Amount	Amount able to be paid off	Amount	Amount able to be paid off
a) Short - term	305,475,578,704	305,475,578,704	235,206,963,747	235,206,963,747
<i>- Some large balances in Trade payables:</i>				
Dong Au Trading and Production Company Limited	2,666,223,433	2,666,223,433	3,907,753,067	3,907,753,067
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	8,295,285,087	8,295,285,087	11,392,041,393	11,392,041,393
KPC Pharmaceuticals, Inc	19,295,404,404	19,295,404,404	18,745,888,869	18,745,888,869

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)*

Laboratorio Italiano	-	-	24,197,333,026	24,197,333,026
Biochimico Farmaceutico Lisa pharma S.P.A				
Inbiotech L.t.d	7,240,797,600	7,240,797,600	9,194,736,030	9,194,736,030
XL Laboratories PVT.,LTD	93,938,509,512	93,938,509,512	16,837,250,486	16,837,250,486
Pharmaunity Co.,Ltd	33,464,433,496	33,464,433,496	33,987,410,018	33,987,410,018
Gracure Pharmaceuticals Limited	10,128,675,725	10,128,675,725	12,949,962,228	12,949,962,228
Concord Biotech Limited	19,981,298,760	19,981,298,760	20,490,547,797	20,490,547,797
Saifen Drugs (Hong Kong)	16,850,808,182	16,850,808,182	7,621,817,561	7,621,817,561

b) Trade payables from related parties: Details are presented in Note VIII.2

13. Advances from customers	30/6/2025 VND	01/01/2025 VND
a) Short - term	151,464,336,894	131,593,255,879

- Some large balances in Advances from customers:

T&T Equipment JSC	-	6,556,194,866
T&T Pharmaceutical and Trading JSC	1,787,705,420	2,779,357,780
Tan Truong Sinh Trading JSC	-	2,911,479,920
Vistar Trading development and Investment JSC	2,294,027,221	820,670,220
Bao Ngan Pharmaceutical Company Limited	-	10,735,707,200
Dong Do Pharmaceutical Company Limited	17,724,547,315	31,178,516,478
TB Vietnam Pharmaceutical Trading Company Limited	30,592,944,421	24,495,082,359
Vietlife Pharmaceutical JSC	1,603,308,000	3,722,000,000
Lam An Pharmaceutical Trading Company Limited	13,000,000,000	11,700,000,000
Tan Dai Cat Pharmaceutical Company Limited	2,900,000,000	3,409,598,360
Danh Minh Pharmaceutical JSC	6,662,995,840	-
Vietnam 1A Pharmaceutical Company Limited	10,420,000,000	-
Dai Thuy Trading and Pharmacy JSC	8,928,359,550	-

b) Advances from customers from related parties: Details are presented in Note VIII.2

14. Taxes and amounts payable to the State budget	01/01/2025	Payable during the period	Paid during the period	Unit: VND 30/6/2025
---	------------	---------------------------	------------------------	------------------------

a) Payables				
Output value added tax	6,639,831	1,074,960,065	838,680,610	242,919,286
Value added tax on imports	-	39,575,286,307	39,575,286,307	-
Import tax	-	6,937,385	6,937,385	-
Corporate income tax	5,070,076,715	8,352,860,985	10,494,507,962	2,928,429,738
Personal income tax	980,614,083	2,052,297,149	2,901,776,824	131,134,408
Housing tax, land rent	-	2,536,120,565	2,536,120,565	-
Resource Tax	-	11,563,200	11,563,200	-
Fees, charges and other payables	-	29,000,000	29,000,000	-
Total	6,057,330,629	53,639,025,656	56,393,872,853	3,302,483,432

b) Receivables				
Output value added tax	622,855,829	-	-	622,855,829
Import tax	8,413,385	6,349,325,741	6,340,912,356	-
Other taxes	-	-	-	-
Total	631,269,214	6,349,325,741	6,340,912,356	622,855,829

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Address: No.10A Quang Trung, Ha Dong Ward, Hanoi City, Vietnam

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/6/2025

Form B 09a - DN/HN

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

15. Loans and obligations under finance lease

Loans

Unit: VND

	30/6/2025		In the period		01/01/2025	
	Amount	Amount able to be paid off	Increases	Decreases	Amount	Amount able to be paid off
a) Short-term	325,692,156,052	325,692,156,052	381,263,054,367	428,844,873,182	373,273,974,867	373,273,974,867
Short-term loans	311,847,448,127	311,847,448,127	381,263,054,367	428,844,873,182	359,429,266,942	359,429,266,942
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch (1)	85,860,521,855	85,860,521,855	93,588,379,871	152,166,320,698	144,438,462,682	144,438,462,682
Joint Stock Commercial Bank for Foreign Trade of Vietnam - Ha Tay Branch (2)	65,393,732,420	65,393,732,420	113,349,658,999	148,040,423,238	100,084,496,659	100,084,496,659
Shinhan Bank Vietnam Limited - Hanoi Branch (3)	50,513,709,028	50,513,709,028	61,288,812,401	66,372,156,289	55,597,052,916	55,597,052,916
Joint Stock Commercial Bank for Investment and Development of Vietnam - Ngoc Khanh Branch (4)	61,213,812,532	61,213,812,532	87,584,862,290	43,549,277,420	17,178,227,662	17,178,227,662
Personal loans (5)	48,865,672,292	48,865,672,292	25,451,340,806	18,716,695,537	42,131,027,023	42,131,027,023
Long-term loans on due date	13,844,707,925	13,844,707,925	-	-	13,844,707,925	13,844,707,925
MUFG Bank, LTD - Hanoi Branch (6)	13,844,707,925	13,844,707,925	-	-	13,844,707,925	13,844,707,925
b) Long-term loans	96,912,955,472	96,912,955,472	-	-	96,912,955,472	96,912,955,472
MUFG Bank, LTD - Hanoi Branch (6)	96,912,955,472	96,912,955,472	-	-	96,912,955,472	96,912,955,472
Total	422,605,111,524	422,605,111,524	381,263,054,367	428,844,873,182	470,186,930,339	470,186,930,339

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

- (1) Credit Contract No. 2209/2024-HĐCVHM/NHCT320-HATAPHAR dated September 23, 2024, has a loan limit of VND 150 billion (which includes debts adjusted by Credit Contract No. 2209/2023-HĐCVHM/NHCT320-HATAPHAR dated September 22, 2023). The purpose of the loan is to supplement working capital for production and business activities. The loan interest rate will be as stated on each debt receipt and valid from the disbursement until the interest rate is adjusted on the twenty-fifth (25th) of each month (or the previous working day if the 25th is not a working day). Each debt has a term specified on the debt receipt, but it will not exceed 5 months per contract from the time of loan disbursement. The limited maintenance period will extend until September 23, 2025. This loan is unsecured.
- (2) Loan Agreement No. 04/25/QLN/HM/VCBTHN dated February 06, 2025 attached to Credit contract No. 04/25/QLN/CTD/VCBTHN dated February 06, 2025, Letter of Credit Issuance Contract No. 04/25/QLN/HMLC/VCBTHN dated February 06, 2025, Credit Guarantee Contract No. 04/25/QLN/HMBL/VCBTHN dated February 06, 2025 and the amended and supplemented dated April 4, 2025, has a loan limit of VND 200 billion (which includes the loan contract No. 37/23/QLN/HM/VCBTHN dated October 17, 2023). The purpose of the loan is to finance legal, reasonable, and valid short-term credit needs that support production and business activities, and not for asset investment activities. The Company's fixed interest rate will be specified for each debt, with a maximum loan term of 05 months. The credit term is 12 months from the date of signing this contract or until February 19, 2026, whichever comes first. This loan is unsecured.
- (3) Credit contract No. 130002065517 dated August 16, 2019, and Extension - Amendment Supplement No.130002065517/10 dated September 05, 2024, extending the limit until August 15, 2025, has a loan limit of VND 80 billion, intended to provide working capital for production and business activities; Loan Interest Rate: for a fixed interest rate, the rate will remain constant throughout the loan term as specified in each Loan Withdrawal Application or Debt Acknowledgement; For an adjustable interest rate, the rate will be based on the 3-month MFC reference interest rate plus a margin of 0.74% per year, and it will be adjusted every three months during the loan term; The credit term specified in each debt acknowledgment document does not exceed 3 months per contract; The credit term is 05 years from the date of signing the contract, this loan is unsecured.
- (4) Credit Limit Contract No. 01/2025/177578/HDTD, dated June 10, 2025, establishes a credit limit with a maximum amount of VND 200 billion. This loan serves to supplement working capital, provide guarantees, and open letters of credit (L/C). The interest rate will be determined for each contract based on the bank's interest rate policy at that time. The duration of the credit limit extends from the date of signing this contract. This loan is unsecured.
- (5) Personal loans are offered based on individual loan contracts to support the Company's production and business activities. The loan term is less than 12 months, with an interest rate ranging from 0.033% to 0.4% per month.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)*

(6) Long-term Facility letter No. FL/053/22 dated August 02, 2022, Amendment agreement No. 02 dated January 17, 2023, Amendment agreement No. 03 dated December 27, 2023 of Long-term Facility Letter No. FL/053/22 dated August 02, 2022, the aggregate principal sum of the Facility shall not exceed VND 235 billion. The loan term until December 31, 2032, the Facility shall be used for Capital Expenditure/Factory Construction and for no other purpose. The specific interest rate for the first interest period in respect of an advance specified in a request for Advance which forms an inseparable part of such request shall be legally bound from the moment of the Customer and the Bank agree to such interest rate (whether orally or otherwise) and the request for Advance is deemed to have been accepted by the Bank from that moment thereof. The specific interest rate and other terms of the Advance shall be thereafter documented for evidentiary purposes in a notice (the "Advance") delivered by the Bank to the Customer. This loan is secured by the letter of guarantee issued by Aska Pharmaceutical Holdings Co., Ltd dated August 02, 2022. The first installment of each Advance shall be on the last Business day of December 2025, the subsequent installment shall be made every 12 months thereafter.

c) Loans as related parties: Details are presented in Note VIII.2

16. Accrued expenses	30/6/2025	01/01/2025
	VND	VND
Short-term		
Accrued interest expense	116,731,054	162,743,579
Accrued 60th Anniversary Company Expenses	2,009,800,025	-
Total	2,126,531,079	162,743,579

17. Unearned revenue	30/6/2025	01/01/2025
	VND	VND
Short-term		
Unearned revenue from leases	1,497,365,896	909,298,387
Total	1,497,365,896	909,298,387

18. Other payables	30/6/2025	01/01/2025
	VND	VND
a) Short-term	809,239,523	608,008,522
Insurance	444,619,035	564,338,463
Other payables	364,620,488	43,670,059
b) Long-term	4,843,500,000	4,879,500,000
Long-term collaterals, deposits received	4,843,500,000	4,879,500,000
Total	5,652,739,523	5,487,508,522

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Address: No.10A Quang Trung, Ha Dong Ward, Hanoi City, Vietnam

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the period from 01/01/2025 to 30/6/2025

Form B 09a - DN/HN

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

19. Owner's equity

19.1 Movement in owner's equity

Items	Owner's contributed capital	Share premium	Other owners' equity	Treasury shares (*)	Retained earnings	Total
						Unit: VND
Balance as at 01/01/2024	823,417,730,000	97,320,000,000	26,612,306,630	(8,083,874,357)	88,257,122,317	1,027,523,284,590
Profit in previous year	-	-	-	-	71,771,819,452	71,771,819,452
Dividend payment for 2023	-	-	-	-	(40,096,750,000)	(40,096,750,000)
Interim dividend payment for 2024	-	-	-	-	(40,096,750,000)	(40,096,750,000)
Other decreases	-	-	-	-	(304,624,280)	(304,624,280)
Balance as at 31/12/2024	823,417,730,000	97,320,000,000	26,612,306,630	(8,083,874,357)	79,530,817,489	1,018,796,979,762
Profit in this period	-	-	-	-	34,485,901,629	34,485,901,629
Other decreases (1)	-	-	-	-	(531,684,054)	(531,684,054)
Balance as at 30/6/2025	823,417,730,000	97,320,000,000	26,612,306,630	(8,083,874,357)	113,485,035,064	1,052,751,197,337

(1) Other decreases are due to Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC setting aside a welfare reward fund and a reward fund for the executive board from 2024 profits corresponding to the ratio of non-controlling shareholders.

(*) The book value of shares purchased by the subsidiary from the parent company prior to July 01, 2015.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

19.2 Details of owner's equity contribution

	30/6/2025	01/01/2025
	VND	VND
Hanoi Investment Fund for Development	30,978,660,000	30,978,660,000
ASKA Pharmaceutical Co., Ltd	329,752,390,000	321,810,390,000
Le Van Lo	46,199,910,000	46,199,910,000
Ngo Van Chinh	20,178,110,000	20,178,110,000
Hoang Van Tue	32,866,560,000	32,866,560,000
Le Viet Linh	52,219,860,000	52,219,860,000
Le Anh Trung	30,653,390,000	30,653,390,000
Le Xuan Thang	32,004,810,000	32,004,810,000
Ngo Tuan Viet	5,000,000,000	5,000,000,000
Others	243,564,040,000	251,506,040,000
Total	823,417,730,000	823,417,730,000

19.3 Capital transactions with owners, dividend distribution and shared profit

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
Owners' contributed capital	823,417,730,000	823,417,730,000
Contributed at current period's opening balance	823,417,730,000	823,417,730,000
Contributed capital increase during the period	-	-
Contributed at current period's closing balance	823,417,730,000	823,417,730,000
Paid dividend, shared profit	-	41,170,130,000

19.4 Shares

	30/6/2025	01/01/2025
	Shares	Shares
Number of shares registered for issue	82,341,773	82,341,773
Number of shares issued to the public	82,341,773	82,341,773
- Ordinary shares	82,341,773	82,341,773
- Preferred shares	-	-
Number of shares bought back	1,513	1,513
- Ordinary shares	1,513	1,513
- Preferred shares	-	-
Number of outstanding shares in circulation	82,340,260	82,340,260
- Ordinary shares	82,340,260	82,340,260
- Preferred shares	-	-
Par value of outstanding shares: VND 10,000/share		

19.5 Dividends

Dividends declared after the end of the accounting period:

- Dividends declared on ordinary shares: no

- Dividends declared on preferred shares: no

Unrecorded cumulative preferred shares dividends: no

19.6 Funds of the Company

Unit: VND

Items	01/01/2025	Increase	Decrease	30/6/2025
Investment and development fund	10,749,248,213	-	-	10,749,248,213
Total	10,749,248,213	-	-	10,749,248,213

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

20. Off Interim Consolidated Balance Sheet items

	30/6/2025	01/01/2025
<i>Foreign currencies</i>		
USD	4,122.55	8,883.21
EUR	365.76	311.93

VI. Additional information for items presented in the Interim Consolidated Income Statement

1. Gross revenue from goods sold and services rendered

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Revenue		
Revenue from sales of finished products	327,331,858,754	352,407,016,035
Revenue from sales of goods	743,237,704,125	647,285,270,979
Total	1,070,569,562,879	999,692,287,014

b) Revenue with related parties: Details are presented in Note VIII.2

2. Revenue deductions

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Sales returns	209,869,070	243,758,050
Total	209,869,070	243,758,050

3. Net revenue from goods sold and services rendered

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Net Revenue		
Net revenue from sales of finished products	327,121,989,684	352,163,257,985
Net revenue from sales of goods	743,237,704,125	647,285,270,979
Total	1,070,359,693,809	999,448,528,964

b) Net Revenue with related parties: Details are presented in Note VIII.2

4. Cost of sales

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Cost of finished products sales	236,283,235,672	269,874,528,825
Cost of goods sales	726,216,905,808	628,678,912,652
Inventory handling costs	533,904,121	-
Total	963,034,045,601	898,553,441,477

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

5. Financial income

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
Income from sale of investments	4,712,434,421	-
Bank interest	3,109,601,310	4,446,506,218
Gain from deferred payment, payment discounts	7,756,649,265	4,058,212,278
Exchange rate difference gain arising during the period	694,108,863	208,464,190
Others	-	457,867,785
Total	16,272,793,859	9,171,050,471

6. Financial expenses

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
a) Financial expenses		
Interest expense	7,127,225,787	6,429,048,594
Exchange rate difference losses arising during the period	818,860,074	3,263,802,929
Loss from exchange rate difference due to revaluation at the period end	5,299,727,203	1,192,027,911
Others	-	832,993,717
Total	13,245,813,064	11,717,873,151

b) Financial expenses with related parties: Details are presented in Note VIII.2

7. Other income

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
Rental income	7,062,215,655	5,951,646,565
Liquidation of fixed assets	113,636,364	-
Other income	277,388,634	842,799,576
Total	7,453,240,653	6,794,446,141

8. Other expenses

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
Tax collection and penalties for late payments, administrative penalty	96,205,582	8,576,831
VAT is not refundable	534,173,474	-
Other expenses	19	-
Total	630,379,075	8,576,831

9. Selling expenses and general and administration expenses

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
a) Selling expenses incurred in the period	15,716,331,981	15,595,150,935
Staff expenses	9,059,246,158	9,493,493,047
Materials, packaging expenses	220,082,292	230,005,178
Tool, equipment expenses	52,131,060	61,036,840

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

Depreciation of fixed assets	300,477,432	240,629,274
External services expenses	1,427,234,974	458,385,946
Others expenses	4,657,160,065	5,111,600,650
b) General administration expenses incurred in the period	60,866,596,979	49,610,260,220
Staff expenses	26,339,021,940	18,343,306,940
Management material costs	1,803,708,006	2,015,204,358
Office equipment expenses	4,861,630,843	2,596,211,125
Fixed asset depreciation	1,191,917,672	1,036,392,495
Taxes, fees and charges	1,570,698,251	1,817,214,394
Provision expenses	303,656,290	1,834,651,660
External services	8,414,572,666	7,206,327,883
Other expenses	16,381,391,311	14,760,951,365
c) Deduction from general administration expenses	(90,806,801)	(181,748,210)
Reversal of provisions for accounts receivable	(90,806,801)	(181,748,210)
10. Production cost by factor		
	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Material cost	173,932,400,089	201,831,764,998
Labour cost	49,559,444,599	45,460,138,568
Depreciation expenses	11,930,613,214	9,337,403,254
External services	18,159,824,195	12,056,103,356
Other expenses	32,018,208,967	31,875,693,435
Total	285,600,491,064	300,561,103,611
11. Current corporate income tax expense		
	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Corporate income tax expense calculated on current taxable income	8,352,860,985	8,106,682,346
Adjustment of Corporate income tax expense in prior years into current	-	-
Corporate income tax this year	-	-
Total current corporate income tax expense	8,352,860,985	8,106,682,346
12. Basic earnings per share		
	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Accounting profit after corporate income tax	34,485,901,629	33,321,771,674
Adjustments of increase or decrease in accounting profit to determine profit or loss allocating to shareholders holding common shares:	-	-
Adjustments of increase	-	-
Adjustments of decrease	-	-
- Appropriated Welfare and bonus fund (*)	-	-
Profit or loss shared among shareholders holding common shares	34,485,901,629	33,321,771,674
+ Average outstanding common shares in the period	82,340,260	82,340,260
+ Basic earnings per share	418.82	404.68

(*) The profit used to calculate basic earnings per share does not exclude the amount allocated to the Welfare and bonus fund.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

VII. Additional information for items presented in the Interim Consolidated Cash Flow Statement

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
1. Actual receipt of borrowing amounts in the period		
Proceeds from borrowings under normal agreement	381,263,054,367	324,607,532,614
2. Principal amount paid in the period		
Payment of borrowing principal under normal agreement	428,844,873,182	452,036,704,645

VIII. Other information

1. Subsequent events after reporting date

According to the Resolution of the Board of Management of Hatay Pharmaceutical Joint Stock Company No. 566/NQ-DHT dated July 24, 2025, the Board of Management approved the organization of an extraordinary General Meeting of Shareholders in 2025 to authorize the issuance of bonus shares to existing shareholders at a rate of 10% from the Company's surplus and profits.

The Board of Management confirms that, in all material respects, apart from the above event there are no unusual events arising after the balance sheet date that affect the financial position and operation of the Company and need to be adjusted or presented on the Consolidated Financial Statements for the period from 01/01/2025 to 30/6/2025.

2. Transactions and balances with related parties

Related parties of the Corporation include: key members, individuals who are related to key members and other related parties.

List of related parties:

Related parties	Relationship
Southern Hataphar Company Limited	Associate
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	Associate
Mr. Le Van Lo	Chairman
Mr. Hiroyasu Nishioka	Member of Board of Directors
Mr. Keisuke Oshio	Member of Board of Directors
Mr. Le Xuan Thang	General Director and Member of Board of Directors
Mr. Nguyen Ba Lai	Deputy General Director
Mr. Ngo Tuan Viet	Deputy General Director
Mr. Hoang Van Tue	Chief Accountant and Member of Board of Directors
Mr. Le Anh Trung	Deputy General Director and Vice chairman
Mrs. Le Viet Linh	Deputy General Director and Member of Board of Directors
Mr. Ngo Van Chinh	Head of Board of Supervisory
Mr. Nguyen Ha De	Member of Board of Supervisory
Mr. Kazuhiro Chiku	Member of Board of Supervisory (Appointed on April 14, 2025)
Mr. Dang Dinh Du	Member of Board of Supervisory (Retirement and resignation from September 01, 2024)

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

2.1 During the period, the Company has entered into its significant transactions with related parties as follows:

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
a) Sales		
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	107,562,841,697	127,409,386,850
b) Purchase		
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	46,295,324,209	47,985,818,717
c) Financial expenses		
Mr. Le Van Lo	508,597,522	631,311,887
Mr. Nguyen Ba Lai	71,285,488	81,794,674
Mr. Le Xuan Thang	-	286,985,790
Mr. Hoang Van Tue	29,594,844	194,211,654
Mr. Le Anh Trung	10,360,475	272,882,791
Mrs. Le Viet Linh	-	333,423,300
Mr. Ngo Van Chinh	-	119,234,388

2.2 Balance with related parties

	30/6/2025	01/01/2025
	VND	VND
a) Trade receivables		
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	25,102,003,395	63,375,349,280
b) Advances to suppliers		
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	3,136,254,281	1,709,103,940
c) Trade payables		
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	8,295,285,087	11,392,041,393
d) Short-term loans		
Mr. Le Van Lo	21,780,220,372	7,900,585,989
Mr. Nguyen Ba Lai	3,000,000,000	2,000,000,000
Mr. Hoang Van Tue	989,872,000	980,400,000
Mr. Le Anh Trung	429,301,455	429,301,455

2.3 Income entitled to key management members

Income entitled to key management members in the period as follows:

		From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
		VND	VND
Name	Position		
Mr. Le Van Lo	Chairman	918,732,000	783,331,100
Mr. Hiroyasu Nishioka	Member of Board of Directors	-	-
Mr. Keisuke Oshio	Member of Board of Directors	-	-
Mr. Le Xuan Thang	General Director and Member of Board of Directors	843,371,760	715,855,400

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Consolidated Financial Statements)

Mr. Nguyen Ba Lai	Deputy General Director	679,952,200	638,022,400
Mr. Le Anh Trung	Deputy General Director and Vice chairman	791,024,100	676,204,400
Mrs. Le Viet Linh	Deputy General Director and Member of Board of Directors	792,825,660	672,685,300
Mr. Ngo Tuan Viet	Deputy General Director	544,312,300	162,088,100
Mr. Hoang Van Tue	Chief Accountant and Member of Board of Directors	716,481,960	604,531,200
Mr. Ngo Van Chinh	Head of Board of Supervisory	680,783,400	572,401,400
Mr. Nguyen Ha De	Member of Board of Supervisory	256,591,400	221,832,100
Mr. Kazuhiro Chiku	Member of Board of Supervisory (Appointed on April 14, 2025)	-	-
Mr. Dang Dinh Du	Member of Board of Supervisory (Retirement and resignation from September 01, 2024)	-	345,953,500
Total		6,224,074,780	5,392,904,900

3. Comparative information

Comparative figures are the figures of the audited and reviewed Consolidated Financial Statements for the fiscal year ended 31/12/2024 and Interim Consolidated Financial Statements for the period from 01/01/2024 to 30/6/2024 of Hatay Pharmaceutical Joint Stock Company by Vietnam Auditing and Evaluation Co., Ltd. (VAE).

Hanoi, August 20, 2025

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by



Nguyen Thi Bich Ngoc

Chief Accountant



Hoang Van Tue

General Director



Le Xuan Thang